Exchange: OTC·Updated 02:28 PM EDT
Upcoming Earnings:

Reports: Aug 25After Hours

Estimated EPS

$0.00

Estimated Rev

---

For the full year 2026, Molecular Partners maintains its previously reported forecast with total operating expenses of CHF 45-55 million expected, including approximately CHF 6 million of non-cash effective costs.

Bullish Takeaway

Molecular Partners is advancing its clinical pipeline with the dose escalation of MP0712, the selection of a new CD70 target, and a solid balance sheet expected to fund operations through 2027.

Bearish Takeaway

Molecular Partners incurred a H1 2026 net loss of CHF 26.7 million, experienced a significant decline in cash and shareholders' equity, and remains subject to substantial clinical development and regulatory risks.

Generated by Stocktwits using AI and company-reported earnings data. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult

Advertisement|Remove ads.